ArticleJournal of geriatric cardiology : JGC2026
Association between Chinese herbal medicine and the composite outcome of repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: a prospective cohort study.
Article in Journal of geriatric cardiology : JGC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the association between adjunctive Chinese herbal medicine (CHM) and post-percutaneous coronary intervention (PCI) adverse cardiovascular events in patients with chronic coronary syndrome (CCS), and to identify subgroups that may derive greater benefit from integrative therapy.
methodsThis study included 2274 patients with CCS after PCI: 1155 patients in the guideline-directed medical treatment (GDMT) group and 1119 patients in the integrative Chinese and Western medicine (ICWM) group. Exposure was defined as cumulative CHM treatment for > 6 months per year. The primary endpoint was a composite of repeat revascularization and in-stent restenosis (ISR). Kaplan-Meier survival analysis and multivariable Cox regression models were used to assess associations between treatment strategy and study outcomes.
resultsA total of 1054 patients experienced the primary endpoint, including 575 patients (49.80%) in the GDMT group and 479 patients (42.80%) in the ICWM group. Compared with the GDMT group, the ICWM group had lower cumulative incidences of the primary endpoint, repeat revascularization, and ISR (log-rank
conclusionsIn this prospective cohort study, adjunctive CHM was associated with lower risks of the composite endpoint of repeat revascularization and ISR, as well as its individual components, in patients with CCS after PCI. The observed association appeared more pronounced in patients with prior PCI and those without multivessel coronary artery disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.